2121. Participant Recruitment From Low- and Middle-Income Countries for Pivotal Trials of Drugs Approved by the U.S. Food and Drug Administration : A Cross-Sectional Analysis.
作者: Fareed A Awan.;Andrew B Becker.;Yuetong Wang.;Jonathan Kimmelman.
来源: Ann Intern Med. 2022年175卷12期1675-1684页
Many participants in clinical trials supporting U.S. Food and Drug Administration (FDA) drug approvals are recruited from outside the United States, including from low- and middle-income countries (LMICs). Where participants are recruited for pivotal trials has implications for ethical research conduct and generalizability.
2122. Health Care During Incarceration: A Policy Position Paper From the American College of Physicians.
作者: Newton E Kendig.;Renee Butkus.;Suja Mathew.;David Hilden.; .
来源: Ann Intern Med. 2022年175卷12期1742-1745页
The American College of Physicians (ACP) has a long-standing commitment to improving the health of all Americans and opposes any form of discrimination in the delivery of health care services. ACP is committed to working toward fully understanding and supporting the unique needs of the incarcerated population and eliminating health disparities for these persons. In this position paper, ACP offers recommendations to policymakers and administrators to improve the health and well-being of persons incarcerated in adult correctional facilities.
2125. Correction: Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban and Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation.
来源: Ann Intern Med. 2022年175卷11期1627-1628页
2138. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
作者: Erin K McCreary.;Lara Lemon.;Christina Megli.;Amber Oakes.;Christopher W Seymour.; .
来源: Ann Intern Med. 2022年175卷12期1707-1715页
Monoclonal antibody (mAb) treatment decreases hospitalization and death in high-risk outpatients with mild to moderate COVID-19. However, no studies have evaluated adverse events and effectiveness of mAbs in pregnant persons compared with no mAb treatment.
|